Post the de-merger of its pharmaceutical business into a 100 per cent subsidiary, Vadodara-based Alembic Pharmaceuticals Limited has posted a net profit of Rs 27.56 crore for the quarter ended June 30, 2011.
The company reported sales for the quarter ended June 30 2011 at Rs 344.72 crores, up by 34 per cent compared to Rs 256.62 crores in corresponding quarter previous year.
Alembic Pharmaceuticals' international generics to the regulated markets grew by 127 per cent to Rs 61.15 crore from Rs 26.97 crore over corresponding quarter last year.
EBIDTA margins for the first quarter of fiscal 2011-12 at Rs 50.43 crore up at 14.6 per cent from 11.4 per cent for corresponding quarter last year.
On the domestic front, the company's formulations posted sales of Rs 172.44 crores against Rs 144.96 crores with a 19 per cent growth over the corresponding quarter of the previous year.
A vertically integrated company, Alembic Pharmaceuticals has an ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and intermediates.
